喀什取环的价钱(喀什割包皮25岁) (今日更新中)

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

MANILA, June 14 (Xinhua) -- At least 200 people, mostly children, have been taken to hospitals after allegedly suffering from food poisoning at a birthday party in the northern Philippine province of Bulacan, local newspaper Manila Bulletin reported Tuesday.Most of the victims suffered from stomach and chest pains, diarrhea and vomiting, local health officer Dr. Rizalli Lucas was quoted as saying.The victims claimed the cause of their food poisoning was the spaghetti served during a birthday celebration over the weekend in a village of Calumpit town.James P. de Jesus, mayor of Calumpit, said the situation is now contained and controlled but they still have to implement health measures and to determine the cause of the alleged food poisoning.Police have started investigating the incident.

SAN FRANCISCO, June 28 (Xinhua) -- Google on Tuesday rolled out a new social networking service named "Google+", a long awaited move of the Internet search giant to crack the industry's social trend dominated by Facebook.Unlike Facebook, Google said that the project is designed for sharing with small groups like college roommates and parents. " Today's online services turn friendship into fast food, wrapping everyone in 'friend' paper," Google said in a blog post announcing the new service.Other Google+ features include Sparks, which gathers articles and videos on topics of interests or hobbies; and Hangouts, which allows users join live multi-person video chat.There is also a mobile version of Google+ for smartphones running Google's Android operating system, which enables multi- person text message chats and instant upload of photos from the phone.The Google+ project is currently in field trial and by invitation only. Users can select people from their Gmail contacts and organize them into different groups.Google+ is expected to test whether Google could come back from its past frustration in social networking, such as Buzz, a social networking and messaging too integrated into its Gmail service. Some of Google Buzz's features have been widely criticized for privacy concerns.Market research data show that Facebook has surpassed Google in terms of time spent on each site, a fact that advertisers attach importance to.According to Internet market research company comScore, including YouTube, 180 million people visited Google sites in May, compare to 157.2 million on Facebook. However, Facebook users looked at 103 billion pages and spent an average of 375 minutes on the site, while Google users viewed 46.3 billion pages and spent 231 minutes.In April, Google CEO and co-founder Larry Page reportedly sent out a company-wide memo alerting employees that 25 percent of their annual bonus will be tied to the success or failure of Google's social strategy in 2011.

NANCHANG, Aug. 12 (Xinhua) -- Seventy-seven people were hospitalized after eating lobsters in a city in east China's Jiangxi Province, local authorities said Friday.The residents of the city of Ruichang suffered vomiting and diarrhea after attending a lobster feast Thursday night. The hospitalized residents are all in stable condition.It is believed that the diners might have been sickened by E. coli contamination, according to doctors at the Ruichang People's Hospital.Local authorities are continuing to investigate the case. Citizens suffering from diarrhoea or vomiting receive medical treatment in a hospital in Ruichang City, east China's Jiangxi Province, Aug. 12, 2011

LOS ANGELES, July 5 (Xinhua) -- NASA's Juno spacecraft is 30 days away before its first launch window opens, the Jet Propulsion Laboratory (JPL) announced on Tuesday."One month from today, our first launch window opens at 11:34 a. m. EDT (8:34 a.m. PDT) and lasts 69 minutes," said Jan Chodas, Juno project manager from NASA's JPL in Pasadena, Los Angeles."Our primary launch period is 22 days long, and so if weather or other issues come up on Aug. 5, we have 21 more days to get Juno flying. Once we get Juno into space, it's a five-year cruise to Jupiter.""The launch window is the length of time allotted every day for an attempt to launch the spacecraft," said Chodas. "The launch period is the period of time in days when everything is in the right place to get your mission off to the right start."For a mission like Juno, getting everything in the right place includes considering the size of the rocket and spacecraft, where our home planet -- and in particular Juno's launch pad -- is pointed at any moment, and its location in space relative to other celestial objects like Juno's final target, Jupiter.Juno is scheduled to launch aboard a United Launch Alliance Atlas V rocket from pad 41-C at the Cape Canaveral Air Force Station, Florida.The solar-powered spacecraft will orbit Jupiter's poles 33 times to find out more about the gas giant's origins, structure, atmosphere and magnetosphere and investigate the existence of a solid planetary core.JPL manages the Juno mission for the principal investigator, Scott Bolton, of Southwest Research Institute in San Antonio.The Juno mission is part of the New Frontiers Program managed at NASA's Marshall Space Flight Center in Huntsville, Alaska. Lockheed Martin Space Systems, Denver, built the spacecraft.

来源：资阳报